Effect of tacrolimus on the expression of Park7 in glomerular podocytes injured by puromycin aminonucleoside.

Objectives: To study the effect of puromycin aminonucleoside (PAN) on the apoptosis of mouse podocyte clone 5 (MPC-5) and the expression of recombinant human Parkinson's disease 7 (Park7) and to study the protective mechanism of tacrolimus (FK506) against MPC-5 injury.

Methods: MPC-5 cells were cultured and then divided into three groups: blank control (control), PAN, and FK506. The cells in the PAN group were added with PAN (with a concentration of 50 mg/L) to establish a model of MPC-5 injury, and those in the FK506 group were added with PAN (with a concentration of 50 mg/L) and FK506 (with a concentration of 5 mg/L).

Effects of tacrolimus on autophagy protein LC3 in puromycin-damaged mouse podocytes.

Objective: To investigate the mechanism through which tacrolimus, often used to treat refractory nephropathy, protects against puromycin-induced podocyte injury.

Methods: An model of puromycin-induced podocyte injury was established by dividing podocytes into three groups: controls, puromycin only (PAN group), and puromycin plus tacrolimus (FK506 group). Podocyte morphology, number, apoptosis rate and microtubule associated protein 1 light chain 3 alpha () expression were compared.

Role of CD2-associated protein in podocyte apoptosis and proteinuria induced by angiotensin II.

Podocytes are highly differentiated epithelial cells that form interdigitating foot processes with bridging slit diaphragms (SDs) that regulate renal ultrafiltration. Proteinuria is the most common clinical manifestation of glomerular diseases. Losartan is the traditional renin-angiotensin system (RAS).